23 results about "Intellectual disability" patented technology

Disclosed are compounds, and corresponding methods of treatment, that activate myocyte-specific enhancer factor 2 (MEF2) transcriptional activity that are therefore useful in treating deficits in MEF2C activity found in autism spectrum disorder (ASD), intellectual disability (ID), attention deficit and hyperactivity disorder (ADHD), and in diseases characterized by cognitive decline such as Alzheimer's disease (AD), Lewy body dementia (LED), Frontotemporal dementia (FTD), and other forms of dementia, as well as movement disorders such as Parkinson's disease (PD) and parkinsonism from other causes.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SCN2A RNA in a cell or subject, and in certain instances reducing the amount of SCN2A protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a disease or disorder associated with a voltage-gated sodium channel protein, such as, for example, a Developmental and Epileptic Encephalopathy, an intellectual disability, or an autism spectrum disorder. Such symptoms and hallmarks include, but are not limited to seizures, hypotonia, sensory integration disorders, motor development delays and dysfunctions, intellectual and cognitive dysfunctions, movement and balance dysfunctions, visual dysfunctions, delayed language and speech, gastrointestinal disorders, neurodevelopmental delays, sleep problems, and sudden unexpected death in epilepsy.

A system is provided.SOLUTION: A system comprising: means for recording interactions between a parent and a child of a Mental Disability; means for pre-processing the recorded interactions to train a generative AI; means for the generative AI to communicate with the child after the parent dies; means for the generative AI to monitor the child for anomalous behavior; and means for providing an emergency notification if an anomaly is detected.SELECTED DRAWING: Figure 1

Provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Protocadherin 19 (PCDH19) RNA in a cell or subject, and in certain instances reducing the amount of PCDH19 protein in a cell or subject. Such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodevelopmental disease or disorder. Such neurodevelopmental diseases or disorders include PCDH19 Epilepsy. Such symptoms or hallmarks include seizures, cognitive impairment, intellectual disabilities, autism spectrum disorder, behavioral problems, aggression, anxiety, obsessive-compulsive disorder, hyperactivity, attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD).

CASK-related disorders are caused by mutations in an important regulatory gene in the brain, calcium / calmodulin-dependent serine protein kinase (CASK) and can result in microcephaly with pontine and cerebellar hypoplasia (MICPCH), in addition to intellectual disability, and seizure activity. CASK-related Intellectual Disabilities (CASK-ID) predominantly affect the female population and are classified as X-linked neurodevelopmental disorders. CASK-ID is typically the result of a de novo loss of function mutation. As females have two Xchromosomes, disease causing mutations present with a 50 / 50 expression of mutant and wildtype, due to the mosaicism caused by random X-chromosome inactivation (XCI). This mosaicism presents an interesting therapeutic option of reactivating the intact allele in affected neurons. Disclosed herein are gene editing systems that can enhance in vivo CASK expression.

To provide UBE3A for the treatment of Angelman syndrome.SOLUTION: Angelman syndrome is a genetic neurological disorder with characteristics including delayed development, intellectual disability, severe speech impairment, and problems with movement and balance. Provided herein are polynucleotides, vectors, polypeptides, cells, compositions, kits and methods to treat Angelman syndrome. Provided herein are, for example, the following: a recombinant polynucleotide encoding a Ubiquitin Protein Ligase E3A (Ube3a) polypeptide or protein or a biological equivalent thereof, the Ube3a polypeptide or protein or a biological equivalent thereof comprising one or more naturally occurring or non-naturally occurring glycosylation sites.SELECTED DRAWING: None

An object of the system according to the embodiment is to enable parents of children with developmental disabilities or intellectual disabilities to obtain appropriate information and support.SOLUTION: A system according to an embodiment includes an online platform, a AI chat bot, an analyzer, and a matcher. The online platform is for parents of children with developmental and intellectual disabilities to share information, experience, and receive assistance. The AI chat bot provides appropriate information and advice in response to a question from a parent. The analysis unit analyzes the degree and characteristics of the disorder of the child. The matching unit matches parents having children with similar symptoms on the basis of the result analyzed by the analysis unit.SELECTED DRAWING: Figure 1

The utility model relates to the field of teaching tools. In daily teaching, for children with poor eyesight and intellectual disabilities, learning these basic mathematical knowledge is undoubtedly a huge challenge. Due to their own intellectual disabilities and vision problems, these children find it difficult to clearly see the content of real objects or blackboards, so they lack effective ways to understand and learn knowledge, which makes them encounter many difficulties in the process of studying. In order to solve the above problems, the utility model discloses a comparative size light-sensing operation box for children with special needs, including a circular component, a triangular component, a square component and a spherical component placed inside a storage box. This teaching tool with a luminous function not only meets the needs of children with poor eyesight and intellectual disabilities, so that they can clearly see what they have learned, but also can be assembled into larger objects to adapt to the cognitive ability of children with special needs.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SCN2A RNA in a cell or subject, and in certain instances reducing the amount of SCN2A protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a disease or disorder associated with a voltage-gated sodium channel protein, such as, for example, a Developmental and Epileptic Encephalopathy, an intellectual disability, or an autism spectrum disorder. Such symptoms and hallmarks include, but are not limited to seizures, hypotonia, sensory integration disorders, motor development delays and dysfunctions, intellectual and cognitive dysfunctions, movement and balance dysfunctions, visual dysfunctions, delayed language and speech, gastrointestinal disorders, neurodevelopmental delays, sleep problems, and sudden unexpected death in epilepsy.

This article provides compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SCN2A RNA in cells or subjects, and in some cases, reducing the amount of SCN2A protein in cells or subjects. Such compounds, methods, and pharmaceutical compositions can be used to improve at least one symptom or marker of a disease or disorder associated with voltage-gated sodium channel proteins, such as, for example, developmental and epileptic encephalopathy, intellectual disability, or autism spectrum disorder. Such symptoms and markers include, but are not limited to, seizures, hypotonia, sensory integration dysfunction, delayed and impaired motor development, intellectual and cognitive impairment, motor and balance impairment, visual impairment, language and speech delay, gastrointestinal disorders, delayed neurodevelopment, sleep problems, and sudden unexpected death in epilepsy.

Provided herein are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SCN2A RNA, and in certain cases, the amount of SCN2A protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions can be used to improve at least one symptom or indicia of a disease or disorder associated with a voltage-gated sodium channel protein, such as, for example, developmental and epileptic encephalopathies, intellectual disability, or an autism spectrum disorder. Such symptoms and indicia include, but are not limited to, seizures, hypotonia, sensory integration disorder, motor development delays and dysfunction, intellectual and cognitive dysfunction, motor and balance dysfunction, visual dysfunction, language and speech delays, gastrointestinal disorders, neurodevelopmental delays, sleep problems, and sudden unexpected death in epilepsy.

To provide a system.SOLUTION: A system for supporting settings in a learning environment using a tablet includes: means that allows a teacher to check a method for setting a tablet; and means that performs settings suitable for a child with mental retardation on the basis of the checking means.SELECTED DRAWING: Figure 1

This document provides methods and materials for treating SYNGAP1-associated neurodevelopmental disorders (NDDs; e.g., SYNGAP1-related intellectual disability (SRID)). For example, viral vectors (e.g., adeno-associated viral (AAV) vectors) that include (e.g., are designed to include) nucleic acid encoding a truncated Syngap1 polypeptide (e.g., Syngap1-B:α1 polypeptide) are provided. In some cases, one or more viral vectors provided herein (e.g., AAV vectors that include nucleic acid encoding a truncated Syngap1 polypeptide such as a Syngap1-B:α1 polypeptide) can be administered to a mammal (e.g., a human) having, or at risk for developing, a SYNGAP1-associated NDD (e.g., SRID) to treat the mammal.

To provide a system that estimates emotions of users with intellectual disabilities and provides appropriate responses according thereto.SOLUTION: A system comprises an acquisition unit, an estimation unit, a determination unit, and a response unit. The acquisition unit acquires emotion estimation information for estimating emotions of users with intellectual disabilities. The estimation unit estimates the emotion of a user on the basis of the emotion estimation information acquired by the acquisition unit. The determination unit determines a response according to the emotion of the user estimated by the estimation unit. The response unit executes the response determined by the determination unit.SELECTED DRAWING: Figure 1

The invention is based on the detection of the involvement of the K63-specific deubiquitinase CYLD in the manifestation of autism spectrum disorder in a mouse model. The invention therefore provides methods for the diagnosis of such a disorder as well as methods for the development of new autism diagnostics. Further provided are means and methods for use in therapeutically modulating any manifestation of an autism spectrum disorder, or intellectual disability (ID), in a mammal or associated neuropsychiatric manifestations.

The application discloses a composition for treating intellectual disability and application thereof. The application verifies the effectiveness of the composition in improving the expression level of CAPZA2, restoring synaptic function and improving neural behavior by introducing an AAV virus carrying an hCAPZA2 gene into a CAPZA2 hybrid knockout or mutant mouse model. The application not only provides new hope for the treatment of intellectual disability related to the CAPZA2 gene, but also opens up a new direction for the application of gene therapy in neurodevelopmental diseases.

This item is a wooden partition that is mainly used as a calm down space for people with developmental disabilities, intellectual disabilities, and mental disabilities to temporarily enter in order to block out outside sounds and lines of sight and calm down. The three panels of this item are connected by hinges that can move 360 ​​degrees, and can be used in a straight line, or in a U-shape, N-shape, or other desired angle, as shown in the "Using state perspective view" and "N-shape perspective view". In addition, as shown in the "Enlarged view of the part in use", there is a small gap between the panels, which allows educators to watch over children inside from outside, for example, in schools. Furthermore, as shown in the "Front view", "Plan view", "Perspective view", etc., this item has small protrusions in the upper center of the left and right panels of the three connected panels, and these protrusions can be used to hang tags with strings to notify people that they are in the room.

The present invention provides methods and compositions for diagnosing and treating intellectual disability (ID). The invention also provides methods and compositions for developing and using in-vitro and in vivo models for diagnosis and treatment as well as testing.

1. The name of the product under this design: Pants (Adult Velcro Style). 2. Purpose of this design product: This design product is a pair of Velcro-style pants suitable for people who are bedridden, have limited mobility, or have intellectual disabilities. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the key points of the design: main view. 5. This product is a thin product, and the left view, right view, top view, and bottom view are omitted. 6. Other situations requiring explanation: In the usage state, Figures 1-3 are actual product reference images.

The application discloses a composition for treating intellectual disability, application thereof and a drug screening method. The application verifies the effectiveness of the composition in improving the expression level of CAPZA2, restoring synaptic function and improving neural behavior by introducing an AAV virus carrying an hCAPZA2 gene into a CAPZA2 hybrid knockout or mutant mouse model. The application not only provides new hope for the treatment of intellectual disability related to the CAPZA2 gene, but also opens up a new direction for the application of gene therapy in neurodevelopmental diseases.

The present disclosure provides compounds of Formula (I), and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be useful for inhibiting kinases, e.g., glycogen synthase kinase 3 (GSK3). The provided compounds may be able to selectively inhibit GSK3a, as compared to GSK3P and / or other kinases. The present disclosure further provides pharmaceutical compositions, kits, and methods of use, each of which involve the compounds. The compounds, pharmaceutical compositions, and kits may be useful for treating diseases associated with aberrant activity of GSK3a (e.g., Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder).

Disclosed herein are methods for treating juvenile onset neurological conditions, such as autism (ASD), intellectual disability, or epilepsy, with an inhibitor of N-methyl-D-aspartate receptor (NMDAR). The inhibitor may be NitroSynapsin or a derivative thereof.

SYNGAP1 -related intellectual disability is a genetic neurodevelopmental disorder caused by an insufficient level of SynGAPl. Provided herein are autologous hematopoietic stem and progenitor cells transduced with a lentiviral vector expressing a modified form of SYNGAP1, and methods of making the same, which can be useful in treating patients diagnosed with SYNGAP1 -related intellectual disability.